High frequency of HLA-B44 allelic losses in human solid tumors

被引:23
作者
Cabrera, T
Maleno, U
Lopez-Nevot, MA
Redondo, M
Fernandez, MA
Collado, A
Garrido, F
机构
[1] Univ Granada, Serv Analisis Clin, Hosp Virgen Nieves, Granada 18014, Spain
[2] Univ Granada, Unidad Invest, Hosp Virgen Nieves, Granada 18014, Spain
[3] Hosp Costa Sol, Dept Analisis Clin, Marbella, Spain
关键词
HLA; expression; tumor; LOH; HLA-B44;
D O I
10.1016/S0198-8859(03)00164-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human leukocyte antigen (HLA) class I downregulation, a frequent phenomenon observed in a variety of human tumors, favors tumor immune escape from T-lymphocyte recognition. However, it is not known whether a particular HLA class I allele is lost more frequently than others. To address this question we analyzed HLA class I expression in tumor tissues derived from 300 patients diagnosed as having breast, colorectal, or laryngeal carcinomas. Cryostatic tumor sections and a broad panel of anti-HLA class 1 monoclonal antibodies were used. We found that the HLA-B44 allele was lost more frequently than other HLA class I alleles, and that the difference was not related with changes in HLA-B44 allele frequencies between patients and controls. In addition, we observed that 35176 of the HLA-B44 negative tumors presented HLA haplotype loss associated with loss of hetetozygosity. These tests were performed on DNA samples obtained from microdissected tumor tissues. The results seem to indicate that HLA class I allelic losses are not randomly distributed during tumor development but that some HLA class I alleles, and HLA-B44 in particular, are more frequently downregulated and may play an important role in immune escape mechanisms. Human Immunology (C) American Society for Histocompatibility and Immunogenetics, 2003. Published by Elsevier Inc.
引用
收藏
页码:941 / 950
页数:10
相关论文
共 48 条
[21]  
2-0
[22]   Clinical cancer vaccine trials [J].
Jäger, E ;
Jäger, D ;
Knuth, A .
CURRENT OPINION IN IMMUNOLOGY, 2002, 14 (02) :178-182
[23]  
KAKLAMANIS L, 1992, CANCER SURV, V13, P155
[24]  
KAKLAMANIS L, 1994, AM J PATHOL, V145, P505
[25]   DIFFERENCES IN THE ANTIGENS RECOGNIZED BY CYTOLYTIC T-CELLS ON 2 SUCCESSIVE METASTASES OF A MELANOMA PATIENT ARE CONSISTENT WITH IMMUNE SELECTION [J].
LEHMANN, F ;
MARCHAND, M ;
HAINAUT, P ;
POUILLART, P ;
SASTRE, X ;
IKEDA, H ;
BOON, T ;
COULIE, PG .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (02) :340-347
[26]  
Lewis JW, 1998, EUR J IMMUNOL, V28, P3214, DOI 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.3.CO
[27]  
2-3
[28]   Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors [J].
Luckey, CJ ;
Marto, JA ;
Partridge, M ;
Hall, E ;
White, FM ;
Lippolis, JD ;
Shabanowitz, J ;
Hunt, DF ;
Engelhard, VH .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1212-1221
[29]   Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas:: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21 [J].
Maleno, I ;
López-Nevot, MA ;
Cabrera, T ;
Salinero, J ;
Garrido, F .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (07) :389-396
[30]   Analysis of HLA-E expression in human tumors [J].
Marín, R ;
Ruiz-Cabello, F ;
Pedrinaci, S ;
Méndez, R ;
Jiménez, P ;
Geraghty, DE ;
Garrido, F .
IMMUNOGENETICS, 2003, 54 (11) :767-775